证券代码：688212 证券简称：澳华内镜 公告编号：2025-048 上海澳华内镜股份有限公司 持股 5%以上股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持有股份的基本情况 本次减持计划实施前，顾康、顾小舟及其控制的上海小洲光电科技有限公司 （以下简称"小洲光电"）合计持有上海澳华内镜股份有限公司（以下简称"公 司"）41,822,800 股，占公司总股本的 31.06%。其中小洲光电持有公司股份 3,132,100 股，占公司总股本的 2.33%；顾康持有公司股份 16,950,200 股，占公 司总股本的12.59%；顾小舟持有公司股份21,740,500股，占公司总股本的16.14%。 上述股份来源均为公司首次公开发行前取得的股份，且已于 2024 年 11 月 15 日 起上市流通。 减持计划的实施结果情况 公司于 2025 年 5 月 23 日在上海证券交易所网站（www.sse.com.cn）披露了 《上海澳华内镜股份有限公司持股 5%以上股东减持股 ...

澳华内镜 20250622 摘要 澳华内镜短期业绩受多重因素影响，包括医院采购节奏干扰、医疗设备 以旧换新政策进展缓慢以及公司及行业整体去库存，导致 2024 年业绩 增速受到扰动。 公司高度重视研发投入，研发费用占比维持在 20%以上，加速产品迭代， 新一代 AQ400 超高清内镜系统搭载高光谱技术平台，有望成为差异化 竞争优势。 澳华内镜海外业务发展迅速，尤其在欧美、中东、东南亚等发达国家市 场表现突出，25 财年海外收入占比已达 88.9%，未来提升空间巨大。 预计澳华内镜将在 2026 年迎来经营拐点，高管回购股份彰显发展信心， 新品 AQ-400 上市及海外市场拓展将带来持续增长动力。 2025 年 5 月，公司发布员工持股计划，向不超过 22 名核心管理人员发 放股份募集资金，股票购买价格为 40.02 元，与回购均价一致，展示了 高管对公司的信心。 2026 年被认为是公司经营的重大拐点，主要基于 AQ-400 新品上市、 国内软件行业需求释放以及海外销售高增长等多重因素。 内窥镜行业未来发展模式可能向设备、耗材和维保三位一体格局发展， 同时向消化内镜耗材、软硬件并举发展以及一次性内镜应用等方向 ...

| 名称 | 股） | 比例（%） | （万股） | | 例（%） | | | 时间 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 区间 | | | | | | | | | | 发生直接持股变动的主体： | | | | | | | | | | | | | | | 集中竞价 | ? | | | | 小洲光 | | | | | | | 2025/6/16- | | | 电 | | | | | | | 2025/6/16 | | | | | | | | 其他：____ | | | | | 未发生直接持股变动的主体： | | | | | | | | | | 顾康 | 1,695.0200 | 12.59 | 1,695.0200 | 12.59 | / | | / | | | 顾小舟 | 2,174.0500 | 16.14 | 2,174.0500 | 16.14 | / | | / | | | 合计 | 4,182.2800 | 31.06 | 4,140.7850 | 30.75 | -- | | -- | | | 注：以上数据如有差异， ...

Investment Rating - Industry investment rating: Outperform the market (expected to outperform the CSI 300 index by more than 5% in the next 6 months) [23] Core Insights - The medical device sector is experiencing a significant recovery in bidding activities, driven by ongoing equipment updates and the active participation of county-level medical communities [3][5] - The overall scale of new equipment bidding in China has shown a month-on-month improvement since January 2025, with procurement amounts reaching 174 billion, 113 billion, 140 billion, 153 billion, and 134 billion yuan from January to May, respectively, reflecting year-on-year growth rates of +41%, +77%, +113%, +85%, and +69% [3][10] - Major companies in the industry are benefiting significantly from the recovery in bidding activities, with notable increases in procurement amounts for ultrasound, CT, MRI, and other imaging devices [4][11] Summary by Sections Equipment Update and County Medical Community Efforts - Since March 2025, numerous county medical communities have initiated medical equipment update projects, leading to large-scale procurement orders worth billions of yuan [3][10] - The procurement scope includes various imaging devices such as CTs, ultrasound diagnostic equipment, and MRIs, with significant activity reported in several provinces [3][10] Procurement Scale and Growth - In May 2025, procurement amounts for various devices were as follows: ultrasound 16.63 billion yuan (yoy +103%), CT 18.54 billion yuan (yoy +108%), MRI 15.06 billion yuan (yoy +102%), DR 4.12 billion yuan (yoy +236%), DSA 6.96 billion yuan (yoy +79%), and gastrointestinal endoscopes 3.81 billion yuan (yoy +58%) [4][11][14] Domestic Company Trends - Domestic companies are showing a bidding trend that aligns with the overall industry, with notable performances in May 2025: Mindray 8.19 billion yuan (yoy +56%), United Imaging 7.83 billion yuan (yoy +11%), Kaili 1.10 billion yuan (yoy +137%), and Aohua 0.35 billion yuan (yoy +242%) [4][17] Investment Recommendations - The report suggests focusing on leading domestic companies that are enhancing their high-end and intelligent medical device offerings, such as Mindray, United Imaging, Kaili, and Aohua [5][21]

Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 64 yuan [1][10]. Core Views - The company is expected to experience a turning point as it clears inventory and launches new products, particularly with the anticipated release of the next-generation AQ-400 endoscope system in the second half of 2025 [7][9]. - Despite facing performance pressure in 2024 and 2025 due to external factors, the company continues to make progress in R&D and overseas market expansion, which are expected to drive significant growth in 2026 [8][9]. Summary by Sections 1. Impact of External Environment - The company is undergoing a two-year adjustment period in 2024 and 2025 due to ongoing anti-corruption measures affecting hospital equipment procurement [13]. - The national push for medical equipment upgrades has seen slow execution in some regions, impacting revenue recognition for the company [14][17]. 2. R&D and Overseas Market Development - The company has increased R&D investment, focusing on new product development, including the upcoming AQ-400 system, which is expected to be approved for market release in late 2025 [30][32]. - The overseas market presents significant growth potential, with the company’s overseas revenue growth outpacing domestic growth, reaching 42.7% in 2024 [38][44]. 3. Anticipated Breakthrough in 2026 - The company’s share buyback plan and employee stock ownership plan reflect management's confidence in future growth [45]. - The launch of the AQ-400 is expected to drive substantial sales growth in 2026, similar to the sales patterns observed with previous product launches [49][51]. 4. Long-term Industry Outlook - The soft endoscope industry is characterized by strong monopolistic structures and significant market potential, with opportunities for companies to transition towards a semi-consumable business model [9][14]. - The industry is expected to benefit from ongoing trends in minimally invasive surgical instruments and disposable endoscopes, which are seen as future growth directions [9][14].

Investment Rating - The industry investment rating is "Outperform the Market" [4][46]. Core Viewpoints - The total bid amount for medical devices in May 2025 reached 13.43 billion yuan, representing a year-on-year increase of 69% and a cumulative total of 71.45 billion yuan from January to May, with a year-on-year growth of 72% [5][11]. - Domestic medical device companies showed significant growth, with notable increases in ultrasound and endoscope categories [6][20][23]. - Imported brands also experienced rapid growth, particularly in CT equipment, which saw a year-on-year increase of 282% for Siemens in May [7][35]. Summary by Sections Medical Device Procurement Overview - The total bid amount for May 2025 was 13.43 billion yuan, a 69% increase year-on-year, while the cumulative total for January to May was 71.45 billion yuan, up 72% year-on-year [11][12]. Domestic Brands - Major domestic companies like Mindray, United Imaging, and Aohua Endoscopy reported substantial growth in bid amounts, with Mindray achieving 8.19 billion yuan in May, a 56% increase year-on-year [17][18]. - Aohua Endoscopy's bid amount in May was 0.35 billion yuan, reflecting a remarkable 242% year-on-year growth [20][21]. - Other companies like KAILI and Shanfeng also reported significant increases, with KAILI's bid amount growing by 137% in May [23][24]. Imported Brands - Philips reported a bid amount of 6.11 billion yuan in May, a 62% increase year-on-year, while Siemens achieved 11.57 billion yuan, marking a 112% increase [32][35]. - GE's bid amount reached 9.54 billion yuan in May, reflecting a 47% year-on-year growth [38][39]. - The CT segment for Siemens saw a staggering 282% increase in May, highlighting the strong demand for advanced imaging technologies [35][36].

Core Viewpoint - Auhua Endoscopy (688212.SH) announced a significant change in shareholder equity, with a reduction in shares held by major shareholders, which may indicate a shift in investment strategy or liquidity needs [1][3]. Shareholder Equity Changes - As of June 16, 2025, Xiaozhou Optoelectronics reduced its holdings by 414,950 shares, decreasing its total shares from 41,822,800 to 41,407,850, representing a drop from 31.06% to 30.75% of the total share capital [1][2]. - The reduction in shares was executed through centralized bidding, with a total transaction value of approximately 20.8554 million yuan based on the weighted average price of 50.26 yuan per share on June 16 [1][2]. Financial Performance - In 2024, Auhua Endoscopy reported total revenue of 750 million yuan, reflecting a year-on-year growth of 10.54%. However, the net profit attributable to shareholders decreased by 63.68% to 21.0122 million yuan [4]. - The first quarter of 2025 showed a decline in revenue to 124 million yuan, down 26.92% year-on-year, with a net loss of 28.7915 million yuan compared to a profit of 2.7595 million yuan in the same period last year [5].

证券代码：688212 证券简称：澳华内镜 公告编号：2025-047 上海澳华内镜股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度的提示性 公告 上海澳华内镜股份有限公司（以下简称"公司"）持股 5%以上股东顾康、顾小舟 及其一致行动人上海小洲光电科技有限公司（以下简称"小洲光电"）保证向本公司提 供的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 | | ☑控股股东/实际控制人及其一致行动人 □其他 5%以上大股东及其一致行动人 | | --- | --- | | 投资者及其一致行动人的 | | | 身份 | □合并口径第一大股东及其一致行动人（仅适用于 | | | 无控股股东、实际控制人） | | | □其他______________（请注明） | 2.信息披露义务人信息 | 信息披露义务人名称 | | 投资者身份 | 统一社会信用代码 | | --- | --- | --- | --- | | 上海小洲光电科技有限 | □ ☑ | 控股股东/实控人 控股股东/实控人的一致行动人 | 91310112059358 ...

上海澳华内镜股份有限公司（以下简称"公司"）2025 年员工持股计划第 一次持有人会议于 2025 年 6 月 16 日在公司会议室以通讯表决方式召开。出席 会议持有人 22 人，代表公司 2025 年员工持股计划份额 60,000,000 份，占公司 2025 年员工持股计划总份额的 100%。会议由公司副总经理、董事会秘书施晓江 先生召集和主持。会议的召集、召开和表决程序符合公司 2025 年员工持股计划 的有关规定。本次会议形成如下决议： 一、审议通过《关于设立公司 2025 年员工持股计划管理委员会的议案》 根据公司《2025 年员工持股计划管理办法》等相关规定，同意设立 2025 年员工持股计划管理委员会，作为公司 2025 年员工持股计划的日常管理机构， 代表持有人统一管理本员工持股计划，监督本员工持股计划的日常管理，代表 持有人行使除表决权以外的其他股东权利。管理委员会由 3 名委员组成，设管 理委员会主任 1 名。管理委员会委员的任期为 2025 年员工持股计划的存续期。 表决结果：同意 60,000,000 份，占出席持有人会议的持有人所持份额总数 的 100.00%；反对 0 份；弃权 0 ...

Core Viewpoint - Aohua Endoscopy (688212) has experienced a decline in stock price, closing at 52.72 yuan, down 5.65% from the previous week, with a current market capitalization of 7.1 billion yuan [1] Company Announcements - Aohua Endoscopy announced a cash dividend of 0.08 yuan per share (before tax), with the record date set for June 17, 2025, and the ex-dividend date and payment date on June 18, 2025 [1] - The total number of shares eligible for the dividend distribution is 132,166,179 shares, with a total cash dividend amounting to approximately 10.57 million yuan (before tax) [1] - The company has implemented a differentiated dividend distribution due to the repurchased shares not being entitled to profit distribution rights [2] Share Buyback - Aohua Endoscopy's board approved a share buyback plan on January 3, 2025, with a total buyback fund not less than 100 million yuan and not exceeding 200 million yuan [2] - As of April 30, 2025, the company has repurchased 2,499,071 shares, which are excluded from the profit distribution [2]